Table 2.

Characteristics of the 139 accelerated phase chronic myeloid leukemia patients.

Variable
Gender, male/female, n (%)	77/62 (55.4/44.6)
Age (years), median (range)	43.6 (10–78)
Previous therapy
Interferon, n (%)	64 (46.0)
Hydroxyurea, n (%)	60 (43.2)
Others, n (%)	15 (10.8)
Hemoglobin < 10 g/dL, n (%)	28 (20.14)
Platelets > 1000 × 109/L or <100 × 109/L, n (%)	29 (21.86)
Spleen ≥ 10 cm from left costal margin, n (%)	38 (27.34)
PB blasts 10–29%, n (%)	13 (9.35)
PB basophils ≥ 20%, n (%)	6 (4.32)
Clonal evolution (%)	41 (29.5)
WBC ≥ 100 × 109/L, n (%)	10 (7.35)

PB: peripheral blood; WBC: white blood cell.